{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:27:49Z","timestamp":1790245669822,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jtct.2024.10.010","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T13:49:34Z","timestamp":1729604974000},"page":"36-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Shift from Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T Cell Therapy: Results from a Large Retrospective Cohort"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1302-6272","authenticated-orcid":false,"given":"Giovanna","family":"Melica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2201-3091","authenticated-orcid":false,"given":"Alejandro","family":"Luna de Abia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9977-0456","authenticated-orcid":false,"given":"Gunjan L.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Corona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Fein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0794-3226","authenticated-orcid":false,"given":"Parastoo B.","family":"Dahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1944-5053","authenticated-orcid":false,"given":"Sergio A.","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0834-7880","authenticated-orcid":false,"given":"Richard J.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Lia","family":"Palomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Parascondola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amethyst","family":"Saldia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Scordo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni","family":"Shouval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan K.","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.jtct.2024.10.010_bib0001","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2024.10.010_bib0002","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.jtct.2024.10.010_bib0003","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jtct.2024.10.010_bib0004","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jtct.2022.06.019","article-title":"Role of CD19 chimeric antigen receptor T cells in second-line large B cell lymphoma: lessons from phase 3 trials. An expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"28","author":"Perales","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.jtct.2024.10.010_bib0005","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jtct.2024.10.010_bib0006","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1016\/j.jtct.2024.10.010_bib0007","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet Lond Engl"},{"issue":"20","key":"10.1016\/j.jtct.2024.10.010_bib0008","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2024.10.010_bib0009","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2024.10.010_bib0010","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2024.10.010_bib0011","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","article-title":"CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results","volume":"29","author":"Park","year":"2023","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.jtct.2024.10.010_bib0012","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor t cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"10","key":"10.1016\/j.jtct.2024.10.010_bib0013","first-page":"1280","article-title":"Predicting infections in patients with haematological malignancies treated with chimeric antigen receptor T-cell therapies: A systematic scoping review and narrative synthesis","volume":"29","author":"Reynolds","year":"2023","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis"},{"issue":"8","key":"10.1016\/j.jtct.2024.10.010_bib0014","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.jtct.2024.10.010_bib0015","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","article-title":"Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy","volume":"57","author":"Wudhikarn","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2024.10.010_bib0016","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2021","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.jtct.2024.10.010_bib0017","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.jtct.2024.10.010_bib0018","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.10.010_bib0019","doi-asserted-by":"crossref","DOI":"10.1177\/09636897211025503","article-title":"Incidence and risk factors associated with infection after chimeric antigen receptor T cell therapy for relapsed\/refractory B-cell malignancies","volume":"30","author":"Zhu","year":"2021","journal-title":"Cell Transplant"},{"issue":"23","key":"10.1016\/j.jtct.2024.10.010_bib0020","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/bloodadvances.2021004896","article-title":"Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days","volume":"5","author":"Mikkilineni","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.jtct.2024.10.010_bib0021","doi-asserted-by":"crossref","first-page":"ofaa121","DOI":"10.1093\/ofid\/ofaa121","article-title":"Infectious complications following CD19 chimeric antigen receptor T-cell therapy for children, adolescents, and young adults","volume":"7","author":"Vora","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.jtct.2024.10.010_bib0022","doi-asserted-by":"crossref","first-page":"e14157","DOI":"10.1111\/tid.14157","article-title":"Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies","volume":"25","author":"Kampouri","year":"2023","journal-title":"Transpl Infect Dis Off J Transplant Soc"},{"issue":"16","key":"10.1016\/j.jtct.2024.10.010_bib0023","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1182\/bloodadvances.2022007474","article-title":"Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma","volume":"6","author":"Little","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jtct.2024.10.010_bib0024","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/cid\/ciz1127","article-title":"Invasive mold infections after chimeric antigen receptor-modified T-cell therapy: a case series, review of the literature, and implications for prophylaxis","volume":"71","author":"Haidar","year":"2020","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"2","key":"10.1016\/j.jtct.2024.10.010_bib0025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s15010-020-01521-5","article-title":"Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper","volume":"49","author":"Los-Arcos","year":"2021","journal-title":"Infection"},{"issue":"8","key":"10.1016\/j.jtct.2024.10.010_bib0026","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2024.10.010_bib0027","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/14787210.2021.1962292","article-title":"Pharmacological management of antifungal agents in pulmonary aspergillosis: an updated review","volume":"20","author":"Echeverria-Esnal","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"Suppl 1","key":"10.1016\/j.jtct.2024.10.010_bib0028","doi-asserted-by":"crossref","first-page":"e14162","DOI":"10.1111\/tid.14162","article-title":"Breakthrough invasive fungal infections on isavuconazole prophylaxis in hematologic malignancy & hematopoietic stem cell transplant patients","volume":"25","author":"Khatri","year":"2023","journal-title":"Transpl Infect Dis Off J Transplant Soc"},{"key":"10.1016\/j.jtct.2024.10.010_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: Building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"issue":"6","key":"10.1016\/j.jtct.2024.10.010_bib0030","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and Update of the Consensus Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"3","key":"10.1016\/j.jtct.2024.10.010_bib0031","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1586\/ehm.10.21","article-title":"Allogeneic hematopoietic cell transplantation: the state of the art","volume":"3","author":"Gyurkocza","year":"2010","journal-title":"Expert Rev Hematol"},{"issue":"8","key":"10.1016\/j.jtct.2024.10.010_bib0032","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jiac.2016.05.006","article-title":"An overview of infectious complications after allogeneic hematopoietic stem cell transplantation","volume":"22","author":"Sahin","year":"2016","journal-title":"J Infect Chemother Off J Jpn Soc Chemother"},{"issue":"9","key":"10.1016\/j.jtct.2024.10.010_bib0033","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1007\/s00277-019-03744-5","article-title":"Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis","volume":"98","author":"Rodr\u00edguez-Veiga","year":"2019","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.jtct.2024.10.010_bib0034","first-page":"1068","article-title":"The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study","volume":"91","author":"Pagano","year":"2006","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.jtct.2024.10.010_bib0035","doi-asserted-by":"crossref","first-page":"myad021","DOI":"10.1093\/mmy\/myad021","article-title":"Real-life epidemiology and current outcomes of hospitalized adults with invasive fungal infections","volume":"61","author":"Monz\u00f3-Gallo","year":"2023","journal-title":"Med Mycol"},{"issue":"1","key":"10.1016\/j.jtct.2024.10.010_bib0036","first-page":"535","article-title":"Bendamustine treatment of haematological malignancies: significant risks of opportunistic viral, fungal and bacterial infections","volume":"27","author":"Wu","year":"2022","journal-title":"Hematol Amst Neth"},{"issue":"3","key":"10.1016\/j.jtct.2024.10.010_bib0037","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s12281-019-00343-9","article-title":"Fungal infections with ibrutinib and other small-molecule kinase inhibitors","volume":"13","author":"Zarakas","year":"2019","journal-title":"Curr Fungal Infect Rep"},{"issue":"17","key":"10.1016\/j.jtct.2024.10.010_bib0038","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood-2017-11-818286","article-title":"Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib","volume":"131","author":"Ghez","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2024.10.010_bib0039","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/cid\/cix687","article-title":"Call for action: invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways","volume":"66","author":"Chamilos","year":"2018","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"1","key":"10.1016\/j.jtct.2024.10.010_bib0040","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2024.10.010_bib0041","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"suppl_1","key":"10.1016\/j.jtct.2024.10.010_bib0042","doi-asserted-by":"crossref","first-page":"i60","DOI":"10.1093\/jac\/dkx450","article-title":"Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies","volume":"73","author":"Epstein","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.jtct.2024.10.010_bib0043","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/bjh.19116","article-title":"Invasive fungal infection following venetoclax and posaconazole co-administration","volume":"203","author":"Reynolds","year":"2023","journal-title":"Br J Haematol"},{"issue":"5-6","key":"10.1016\/j.jtct.2024.10.010_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106692","article-title":"Voriconazole therapeutic drug monitoring and hepatotoxicity in critically ill patients: A nationwide multi-centre retrospective study","volume":"60","author":"Wang","year":"2022","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"10.1016\/j.jtct.2024.10.010_bib0045","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/14787210.2016.1199272","article-title":"Antifungal agents and liver toxicity: a complex interaction","volume":"14","author":"Tverdek","year":"2016","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"3","key":"10.1016\/j.jtct.2024.10.010_bib0046","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000536201","article-title":"Management of patients undergoing CAR-T Cell therapy in Germany","volume":"47","author":"Penack","year":"2024","journal-title":"Oncol Res Treat"},{"issue":"4","key":"10.1016\/j.jtct.2024.10.010_bib0047","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/bloodadvances.2019000952","article-title":"Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management","volume":"4","author":"Pennisi","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2024.10.010_bib0048","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724007279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724007279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T18:51:48Z","timestamp":1736794308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724007279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2666636724007279"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.10.010","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Shift from Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T Cell Therapy: Results from a Large Retrospective Cohort","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}